Figure 3.
Forest plot showing IPTW-weighted associations of primary and secondary outcomes with new users of metformin versus sulfonylureas in whole population (over 50) and stratified for patients above and below 75 years of age. IPTW, inverse probability of treatment weighting; MCI, mild cognitive impairment; PD, Parkinson’s disease.